Press Releases

Investor Relations

NASDAQ: GNCA
$ 9.05 0.00 (0.00%)
Day High: 9.10
Day Low:  8.99
Volume:    20,800
4:00 PM ET
Nov 21, 2014

Delayed ~20 min., by eSignal.

Contact



ir@genocea.com


Press Releases
Date Title and Summary View
Nov 21, 2014 CAMBRIDGE, Mass--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million. ...
Nov 13, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston's Top Places to Work by The Boston Globe. "We're delighted to have been named to the Globe's Top ...
Nov 12, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentat...
Nov 6, 2014 Novel product candidates for genital herpes and pneumococcus both advanced into Phase 2 clinical trials CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate hig...
Nov 5, 2014 Findings reveal evidence of malaria in immune system years after clinical episodes CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of ...
Oct 30, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financ...
Oct 8, 2014 After 12 months, GEN-003 shows durable reduction in genital lesions CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies against serious infectious diseases, announced today the prese...
Sep 23, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protecti...
Sep 19, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the BioCentury 21st Annual NewsMakers in the Biotech Industr...
Sep 16, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that the peer-reviewed journal Virology has published a paper describing how Genocea used it's ATLAS™ platform ...
Sep 11, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company's universal vaccine candidate against pneumococcus. ...
Sep 11, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the comp...
Sep 6, 2014 GEN-004 Shown to Induce Antibody and TH17 Responses CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an in...
Aug 6, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014. ...
Jul 30, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on August 6, 2014 at 9:00 a.m. ET to discuss financial...
Jul 22, 2014 Immunogenicity Data from Phase 1/2a Trial Highlighted at 39th Annual International Herpesvirus Workshop CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, tod...
Jul 21, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company's immunotherapy candidate against herpes ...
Jul 16, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to...
Jul 14, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in ...
Jul 1, 2014 - Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announ...
Jun 23, 2014 - Phase 2a study to commence in the third quarter of 2014 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase ...
May 6, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported its financial results for the first quarter ended March 31, 2014. "During the first quarter, Geno...
Apr 29, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on May 6, 2014 at 9:00 a.m. ET to discuss financial r...
Apr 24, 2014 Dr. David A. Sinclair Joins Annual List of World's 100 Most Influential People CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that TIME m...
Apr 7, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the appointment of Jonathan Poole to the position of chief financial officer. Mr. Poole joins Genocea from Shire...
Apr 2, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Needham & Com...
Apr 1, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced today that it has been added to the Russell 3000® and Russell 2000® Indices as part of Russell Investments' first ...
Mar 24, 2014 GEN-003 results for ongoing Phase 1/2a clinical study presented at World Vaccine Congress CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simple...
Mar 3, 2014 -- Joint Effort Extends Application of Company's ATLAS™ Platform into Cancer with Initial Focus on Melanoma -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company pioneering novel T cell vaccines and immunotherapies, today announced a ...
Feb 25, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Cowen and Comp...
Feb 10, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share. After underwriting discounts and commissions and estimated offering expenses, Genocea received net ...
Feb 5, 2014 Cambridge, MA, February 5, 2014 - Genocea Biosciences, Inc. today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 825,...
Dec 23, 2013
PDF
Add to Briefcase
Dec 5, 2013
PDF
Add to Briefcase
Nov 18, 2013
PDF
Add to Briefcase
Sep 12, 2013
PDF
Add to Briefcase
Sep 5, 2013
PDF
Add to Briefcase
Aug 28, 2013
PDF
Add to Briefcase
Aug 12, 2013
PDF
Add to Briefcase
Aug 2, 2013 ************** Genocea Biosciences Fast Facts Vaccine Market Vaccine market grew to ~$42 Billion in 2012 Multiple targets remain (Chlamydia, Hepatitis, HIV, HSV-2, Malaria, TB) Herpes (HSV-2) Therapeutic Vaccine Candidate Estimated size of ...
Mar 18, 2013
PDF
Add to Briefcase
Mar 12, 2013
PDF
Add to Briefcase
Oct 10, 2012
PDF
Add to Briefcase
Aug 15, 2012
PDF
Add to Briefcase
Aug 5, 2012
PDF
Add to Briefcase
Jun 7, 2012
PDF
Add to Briefcase
Apr 11, 2012
PDF
Add to Briefcase
Mar 12, 2012
PDF
Add to Briefcase
Jan 3, 2012
PDF
Add to Briefcase
Oct 24, 2011
PDF
Add to Briefcase
Aug 22, 2011
PDF
Add to Briefcase
Aug 16, 2011
PDF
Add to Briefcase
Jun 20, 2011
PDF
Add to Briefcase
Jun 2, 2011
PDF
Add to Briefcase
Apr 28, 2011
PDF
Add to Briefcase
Mar 23, 2011
PDF
Add to Briefcase
Mar 17, 2011
PDF
Add to Briefcase
Mar 4, 2011
PDF
Add to Briefcase
Feb 25, 2011 ************** Genocea Biosciences Inc., a Cambridge-based developer of T cell-based vaccines, took in a venture capital round worth $35 million in January. The size of the deal is one signal of increasing investor confidence in the vaccines industry at a time when pharmaceutical companies are seeing dwindling sales from traditional drug...
Feb 16, 2011
PDF
Add to Briefcase
Feb 1, 2011
PDF
Add to Briefcase
Jan 3, 2011
PDF
Add to Briefcase
Page:
1
Add to Briefcase = add release to Briefcase